Unfortunately, PD-1/PD-L1 antibody, the most popular strategy for immunotherapy treatment, fails to show universal advantage in NSCLC patients, which is presumably attributed to volatile tumor-immune microenvironment [19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.